Nanotechnology based assays for validating protein biomarkers
Nanotechnology based assays for validating protein biomarkers - Instant free sex chat line melbourne
Instead of just one protein, proteomic research assessing patterns in proteins can allow doctors to test thousands of proteins at once, which may reveal the groups of the most common proteins associated with different types of cancer.
Since most cancer cells have changes in their DNA, studying patterns of DNA changes through genomics research may reveal improved tumor markers.
Research and clinical experience have revealed that testing a single protein or other substance in people may not be the most reliable marker of disease.
Other research approaches may determine better tumor markers.
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide.
Although increased expression of prostate-specific antigen (PSA) is an effective indicator for the recurrence of PCa, its intended use as a screening marker for PCa is of considerable controversy.
As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool.
This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in transnational medicine and the drug development process. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.In the last 20 years, a man’s lifetime risk of being diagnosed with PCa has increased considerably, and this is attributed largely to the introduction of PSA screening in the early 1990s [8,9].On the other hand, the number of men dying from PCa has decreased over the same 20 year period as the disease can now be treated more effectively through a wide range of treatment options and at an earlier stage .This review aims to (i) provide an overview of these technologies as well as describe some of the candidate PCa protein biomarkers that have been discovered using them; (ii) address some of the general limitations in the clinical evaluation and validation of protein biomarkers; and (iii) make recommendations for strategies that could be adopted to improve the successful development of protein biomarkers to deliver improvements in personalized PCa patient decision making.Most men will develop prostate cancer (PCa) if they live long enough .A pathologist will then examine these samples, looking at the shapes of individual cells and the patterns they form under a microscope, to make a specific diagnosis.